“China Future Healthcare Rankings 2024” was announced on May 9, 2024 at the 2024 VBEF Future Healthcare Annual Awards Dinner and the official WeChat account of VB Data at the Beijing Beiren Yichuang International Convention and Exhibition Center.
Biomissile was listed on the “2024 VBEF awards-most innovative and creative products in healthcare”.
About “China Future Healthcare Rankings 2024” and “2024 VBEF awards- Most Innovative and Creative Products in Healthcare”.
“China Future Healthcare Rankings”, founded in 2015, is the first innovative medical field list targeting non listed enterprises in China launched by VB100, VB Data, and Eggshell Research Institute. The aim is to select Chinese innovative medical professionals who represent future medical care, discover the core strength of China future healthcare industry, and promote the innovation and transformation process in China. The “2024 China Future Healthcare Rankings” includes, Top 100 Biomedicine Companies; Top 100 Innovative Public Companies In Healthcare; Most Innovative and Creative Products in Healthcare; and Top 100 Biomedicine Companies.
“2024 VBEF awards- Most Innovative and Creative Products in Healthcare” aims to explore and display the innovative products/ solutions that represent innovative technologies, high domestic substitutability, satisfying clinical unmet needs, strong competitiveness, and outstanding industry leading effect in China and global healthcare industry.
About Biomissile
Biomissile Pharmaceuticals Co., Ltd. is a clinical stage biotech company focusing on developing fully human domain antibody (UDABTM) and multi-specific antibody (UDAB-MTM) to fight a range of diseases with global unmet medical needs. We aim to become a premium innovative biopharmaceutical company based on our unique platform technologies, strong pipeline, and outstanding team. We have established five proprietary platforms for rapid antibody discovery and optimization, including the leading platforms for fully human domain antibody (UDABTM) and multi-specific antibody (UDAB-MTM), as well as the largest libraries of phage, yeast and mammalian cell display platforms. Relying on the strong platform technologies, the company has more than 10 innovative candidates under development in a short period of time, including several First-in-Class domain antibodies (VH) and multi-specific UDAB-MTM molecules to specifically activate immune cells in the tumor microenvironment (TME). So far, two leading projects are in clinical stages (in Phase I & II) and the third one is in IND filing stage.
Biomissile has successfully assembled a global, seasoned leadership team in antibody discovery, manufacturing, clinical, registration and business development. The core team members are composed of experts with an average of more than 20 years’ experience in biological R&D and commercialization. The company has a state-of-the-art R&D lab in Shanghai, a future GMP facility in Suzhou, and a global regulatory & BD team in Boston, USA. We are committed to the disruptive innovation of biological drugs to benefit patients worldwide.
Link to the news in Chinese:
https://mp.weixin.qq.com/s/t6wTNTjGqpq76Cy9s3LsAw
BD: bd@biomissile.com
HR: hr@biomissile.com
Website: www.biomissile.com